P&G Intensifies Wellness Push With Latest Acquisition
Procter & Gamble (P&G) will acquire supplements maker Thorne for $3.8 billion in cash from L Catterton, according to the companies. P&G said the deal supports its health and wellness strategy. Thorne had forecast $290 million sales for 2023 and CNBC reported $650 million for 2024. P&G also forecast slower annual sales growth.
How this was made
The 30-second read
Why it matters
A $3.8 billion cash acquisition is a material capital allocation decision that can re-rate P&G’s growth profile and shift attention to supplements margins, while Thorne’s shares become deal-dependent.
Market read
This is a headline M&A catalyst with a disclosed price and strategic rationale, creating tradable deal certainty and target-side takeover dynamics.
What to watch
Deal execution risk (integration, brand performance vs forecasts, and regulatory scrutiny in supplements) could outweigh the demand narrative, especially given Thorne’s prior sales trajectory.
Background
P&G already has supplements and probiotic brands (New Chapter, Metamucil, Align Probiotic) and is expanding into faster-growing health and wellness categories amid competitive M&A in VMS.
Ticker impact
P&G agreed to acquire supplements maker Thorne for $3.8 billion in cash, expanding its health and wellness push.
Near-term sentiment likely positive on strategic growth, but investors may weigh integration and deal economics.
The article discloses deal size, cash consideration, and strategic rationale (wellness demand, preventive care, weight-loss drug tailwinds), which are actionable for M&A and sector positioning.
Market effects
Signals continued consolidation and premiumization in the VMS/supplements space as large consumer goods firms chase wellness growth.
Limited direct regional impact stated; deal is global but primarily US consumer health and supplements focused.
Large cross-border strategic capital allocation into supplements may influence global peers’ M&A expectations and competitive positioning.
Counterpoint
Investors may discount the strategic rationale if P&G’s slower household-staples growth implies the wellness segment is being bought at an inflated multiple.
Key entities
- companyProcter & Gamble
Acquirer, buying Thorne for $3.8 billion cash to deepen its wellness strategy.
- companyThorne
Supplements maker being acquired; previously taken private by L Catterton and later forecasted sales figures are cited.
- private_equityL Catterton
Private equity firm backing the seller, which took Thorne private in 2023 and is exiting with a large return.
- companyUnilever
Peer referenced for its own VMS acquisition activity, indicating sector-wide consolidation.
- companyNestlé
Peer referenced as conducting a strategic review of low-growth VMS brands.
